A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

By 2060, new dementia cases per year could double to one million because of the growing population of older Americans, a ...

The risk of developing dementia may be much higher than previously thought, a study published in the journal Nature Medicine ...

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

Before treatment, patients need a diagnosis confirmed by ... based on a blood test as the enrolment criterion for dementia drug trials. That could pave the way for those blood tests, which look ...

Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...

Our study results forecast a dramatic rise in the burden from dementia in the United States over the coming decades,” said ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type ... healthcare ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

(“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s ty ...